Literature DB >> 24798353

Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.

Brittany Elizabeth Yee1, Nghia Hoang Nguyen, Daniel Lee.   

Abstract

An 18-year-old postpartum woman with HIV, on lamivudine-zidovudine, lopinavir-ritonavir and raltegravir, presented with a 1-week history of rash and fevers. Initially admitted to obstetrics and gynaecology service for treatment of possible endometritis, she was transferred to the HIV medicine service for high fever, respiratory distress, hypotension and tachycardia. On admission, she was febrile (102°F) with findings of cervical and submandibular lymphadenopathy, diffuse morbilliform rash, generalised pruritus, facial oedema, and oedematous hands and feet. Consultations to various specialty services were initiated to rule out infectious, dermatological, rheumatological and drug-induced aetiologies. On the fourth day of hospitalisation, laboratory findings of significant eosinophilia and hepatitis (alanine aminotransferase 147 IU/L and aspartate aminotransferase 124 IU/L), in conjunction with the identification of the timing of medication use, led to a diagnosis of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome secondary to raltegravir. After discontinuing raltegravir and starting prednisone, her DRESS symptoms completely resolved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798353      PMCID: PMC4025249          DOI: 10.1136/bcr-2013-201545

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Hypersensitivity syndrome associated with efavirenz therapy.

Authors:  P Bossi; D Colin; F Bricaire; E Caumes
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

2.  Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.

Authors:  M Lanzafame; P Rovere; G De Checchi; M Trevenzoli; M Turazzini; A Parrinello
Journal:  Scand J Infect Dis       Date:  2001

3.  An unusual abacavir reaction.

Authors:  Julie Fox; Pippa Newton; Rosemarie Daly; Alison Blume; Brett Marett; Linda Greene; Alan Winston
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

4.  DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.

Authors:  Y Bourezane; D Salard; B Hoen; S Vandel; C Drobacheff; R Laurent
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

5.  Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapy.

Authors:  Alice Breining; Amelie Guihot; Dominique Warot; Ana Canestri; Gilles Peytavin; Francois Bricaire; Eric Caumes
Journal:  BMJ Case Rep       Date:  2009-03-17

6.  [Cutaneous, hepatic and hematologic manifestations due to nevirapine: DRESS syndrome?].

Authors:  D Sissoko; F Ajana; X de la Tribonnière; V Baclet; Y Mouton
Journal:  Presse Med       Date:  2000 May 27-Jun 3       Impact factor: 1.228

Review 7.  Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Authors:  Babafemi Taiwo; Robert L Murphy; Christine Katlama
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

8.  Pulmonary hypersensitivity reaction induced by efavirenz.

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

9.  Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.

Authors:  Cristina Gervasoni; Ottavia Vigano; Erika Grinelli; Massimiliano Ortu; Massimo Galli; Stefano Rusconi
Journal:  AIDS Patient Care STDS       Date:  2007-01       Impact factor: 5.078

10.  The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations.

Authors:  Semaan G Kosseifi; Bhuvana Guha; Dima N Nassour; David S Chi; Guha Krishnaswamy
Journal:  J Occup Med Toxicol       Date:  2006-06-06       Impact factor: 2.646

View more
  5 in total

1.  Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.

Authors:  Mark Thomas; Chris Hopkins; Eamon Duffy; Daniel Lee; Pierre Loulergue; Diego Ripamonti; David A Ostrov; Elizabeth Phillips
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

Review 2.  Eosinophilia in patients infected with human immunodeficiency virus.

Authors:  Andrew Chou; Jose A Serpa
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

3.  Difficult clinical management of antituberculosis DRESS syndrome complicated by MRSA infection: A case report.

Authors:  Li Wang; Lin-Feng Li
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients.

Authors:  David Brandariz; Alex Smithson; Vanesa Anton-Vazquez
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec

5.  Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.

Authors:  Pahnwat Tonya Taweesedt; Charles W Nordstrom; Jessica Stoeckel; Igor Dumic
Journal:  Biomed Res Int       Date:  2019-09-24       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.